Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling by array of human metastatic colorectal tumors and definition of signature relating to response to Folfiri and folfox

ABSTRACT: Using whole genome tumor gene expression profiling in patients treated for metastatic colorectal cancer, we attempted to define a signature able to discriminate between responders and non-responders to first-line chemotherapy.

ORGANISM(S): Homo sapiens

SUBMITTER: Audrey Laroche-Clary 

PROVIDER: E-MTAB-333 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml

Similar Datasets

Unknown FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
| S-EPMC4130839 | biostudies-literature
Transcriptomics CRC samples for FOLFOX therapy prediction
2011-11-21 | GSE28702 | GEO
Unknown Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
| S-EPMC3528380 | biostudies-literature
Unknown Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).
| S-EPMC8161763 | biostudies-literature
Unknown Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.
| S-EPMC6700318 | biostudies-literature
Unknown Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).
| S-EPMC6426764 | biostudies-literature
Unknown A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
| S-EPMC6342906 | biostudies-literature
Unknown Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
| S-EPMC6852115 | biostudies-literature
Unknown Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
| S-EPMC6942442 | biostudies-literature
Unknown Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
| S-EPMC3790175 | biostudies-other